Skip to content
value.today
Jazz Pharmaceuticals Inc. logo

Jazz Pharmaceuticals Inc.

Total raised
$80 M
1 round on record
Latest round
$80 M
Jun 2005
First round on record
Jun 2005
Today
Went public
See the company page

Jazz Pharmaceuticals Inc. is listed today as Jazz Pharmaceuticals plc: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Jazz Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2009$7 MPrivate placement after listing$2 to $10 million

Jazz Pharmaceuticals Inc.: Private sale, Jul 2009

Investors in this round

2 investors had bought by the notice of Jul 8, 2009: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Common Stock and Warrants exercisable for Common Stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bruce Cozzad · Executive Officer, Director
  • Carol A. Gamble · Executive Officer
  • Janne L.T. Wissel · Executive Officer
  • Joan E. Colligan · Executive Officer
  • Robert M. Myers · Executive Officer, Director
  • Alan M. Sebulsky · Director
  • Brian C. Cressey · Director
  • E. Alexander Albert · Director
  • James B. Tananbaum · Director
  • James C. Momtazee · Director
  • Kenneth W. O'Keefe · Director
  • Michael W. Michelson · Director
  • Nathaniel M. Zilkha · Director
  • Patrick G. Enright · Director
  • Samuel D. Colella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Bruce C. Cozadd, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 8, 2009. Read the notice at the SEC.

equity, optionsSEC
Mar 2008$120 MPrivate placement after listing$50 to $250 million

Jazz Pharmaceuticals Inc.: Private sale, Mar 2008

Investors in this round

12 investors had bought by the notice of Nov 25, 2009: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$120 M of $125 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: "Offering of $120.0 million principal amount of Senior Secured Notes (""Notes""), warrants to purchase 562,192 shares of Common Stock (""Warrants"") and the underlying shares of Common Stock issuable
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bruce C. Cozadd · Executive Officer, Director
  • Carol A. Gamble · Executive Officer
  • Janne L.T. Wissel · Executive Officer
  • Joan E. Colligan · Executive Officer
  • Robert M. Myers · Executive Officer, Director
  • Alan M. Sebulsky · Director
  • Bryan C. Cressey · Director
  • James B. Tananbaum · Director
  • James C. Momtazee · Director
  • Kenneth W. O'Keefe · Director
  • Michael W. Michaelson · Director
  • Nathaniel M. Zilkha · Director
  • Patrick G. Enright · Director
  • Samuel D. Colella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Item 13(a) represents the principal amount of the Notes sold on 3/14/08 and the current aggregate exercise price of the related Warrants issued on 3/14/08. On 11/10/09, the per share exercise price of the Warrants was reduced from $14.23 to $9.34.”

Signed by Carol A. Gamble, Senior Vice President, General Counsel and Secretary. Source: SEC Form D, newest notice filed Nov 25, 2009. Read the notice at the SEC.

debt, optionsSEC
Jun 2005$80 MNo. 1$50 to $250 million

Jazz Pharmaceuticals Inc.: Raise no. 1, Jun 2005

Investors in this round

12 investors had bought by the notice of Nov 27, 2009: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$80 M of $87 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: "Offering of $80.0 million principal amount of Senior Secured Notes (""Notes""), warrants to purchase 785,728 shares of Common Stock (""Warrants"") and the underlying shares of Common Stock issuable u
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bruce C. Cozadd · Executive Officer, Director
  • Carol A. Gamble · Executive Officer
  • Janne L.T. Wissel · Executive Officer
  • Joan E. Colligan · Executive Officer
  • Robert M. Myers · Executive Officer, Director
  • Alan M. Sebulsky · Director
  • Bryan C. Cressey · Director
  • James B. Tananbaum · Director
  • James C. Momtazee · Director
  • Kenneth W. O'Keefe · Director
  • Michael W. Michelson · Director
  • Nathaniel M. Zilkha · Director
  • Patrick G. Enright · Director
  • Samuel D. Colella · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Item 13(a) represents the principal amount of the Notes sold on 6/24/05 and the current aggregate exercise price of the related Warrants issued on 6/24/05. On 11/10/09, the per share exercise price of the Warrants was reduced from $20.36 to $9.34.”

Signed by Carol A. Gamble, Senior Vice President, General Counsel and Secretary. Source: SEC Form D, newest notice filed Nov 27, 2009. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Jazz Pharmaceuticals plc, its revenue in fiscal 2025 came from these product and service lines: Product sales, net $4.02 billion (94%), Total Neuroscience $2.88 billion (67%), Xywav $1.66 billion (39%), Total Oncology $1.13 billion (26%), Epidiolex/Epidyolex $1.06 billion (25%).

    Annual report (SEC XBRL) · Dec 2025

  • Jazz Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2009).

    SEC Form D · Nov 2009

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2009

Products and services#

No products or services of Jazz Pharmaceuticals Inc. are on record.

Investors#

No investor of Jazz Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 12 investors.

Largest shareholders today

Institutions holding Jazz Pharmaceuticals plc shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Jazz Pharmaceuticals Inc.
NameRoleNamed in
Bruce C. CozaddExecutive officerNov 2009
Carol A. GambleExecutive officerNov 2009
Janne L.T. WisselExecutive officerNov 2009
Joan E. ColliganExecutive officerNov 2009
Robert M. MyersExecutive officerNov 2009
Bruce CozzadExecutive officerJul 2009
Alan M. SebulskyDirectorNov 2009
Bruce C. CozaddDirectorNov 2009
Bryan C. CresseyDirectorNov 2009
James B. TananbaumDirectorNov 2009
James C. MomtazeeDirectorNov 2009
Kenneth W. O'KeefeDirectorNov 2009
Michael W. MichelsonDirectorNov 2009
Nathaniel M. ZilkhaDirectorNov 2009
Patrick G. EnrightDirectorNov 2009
Robert M. MyersDirectorNov 2009
Samuel D. ColellaDirectorNov 2009
Michael W. MichaelsonDirectorNov 2009
Brian C. CresseyDirectorJul 2009
Bruce CozzadDirectorJul 2009
E. Alexander AlbertDirectorJul 2009

About

Irish tax-registered pharmaceutical corporation.

Went public since 2007. Its SEC number is that of a company listed on a stock exchange.